Non-GLP-1 diabetes medications
SGLT2 inhibitors, DPP-4 inhibitors, insulins, sulfonylureas, metformin, dual-action agents. Denials commonly involve step therapy and brand-vs-generic.
What this class is
Non-GLP-1 diabetes drugs span SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) with cardiovascular and renal benefits; DPP-4 inhibitors (sitagliptin, linagliptin); insulins (long-acting analogs, short-acting analogs, rapid-acting, NPH, regular); sulfonylureas; metformin and combinations; thiazolidinediones; alpha-glucosidase inhibitors. Each class has specific indication, contraindication, and monitoring requirements.
Representative drugs
- SGLT2 (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin)
- DPP-4 (sitagliptin, linagliptin, saxagliptin)
- Insulin glargine (Lantus, Basaglar, Toujeo)
- Insulin aspart (Novolog, Fiasp)
- Insulin lispro (Humalog, Admelog)
- Metformin and combinations
Common denial patterns
- Step therapy requiring older agents before SGLT2
- Non-formulary for newer brand insulins
- Quantity limit on insulin pen
- Brand vs biosimilar/generic step
Clinical guidelines that win appeals
- ADA Standards of Care 2024
Frequently asked questions
What is non-glp-1 diabetes medications?
Non-GLP-1 diabetes drugs span SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) with cardiovascular and renal benefits; DPP-4 inhibitors (sitagliptin, linagliptin); insulins (long-acting analogs, short-acting analogs, rapid-acting, NPH, regular); sulfonylureas; metformin and combinations; thiazolidinediones; alpha-glucosidase inhibitors. Each class has specific indication, contraindication, and monitoring requirements.
What are the common denial patterns?
Step therapy requiring older agents before SGLT2; Non-formulary for newer brand insulins; Quantity limit on insulin pen; Brand vs biosimilar/generic step.
Which clinical guidelines support appeals?
ADA Standards of Care 2024.
Related
- Diabetes drugs & insulinInsulin analogs, GLP-1 for T2D, SGLT2, DPP-4, Afrezza, pump supplies, glucagon rescue
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
Appeal a non-glp-1 diabetes medications denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com